https://www.selleckchem.com/pr....oducts/bgj398-nvp-bg
EAEs were more frequent among older patients. The cabazitaxel safety profile was manageable across age groups. Clinical trial data showed that cabazitaxel improved survival versus abiraterone/enzalutamide with manageable side effects in patients with metastatic castration-resistant prostate cancer who had previously received docetaxel and the alternative agent (abiraterone/enzalutamide), irrespective of age. Clinical trial data showed that cabazitaxel improved survival versus abiraterone/enzalutamide with manageable side effec
Like
Comment
Share
